IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Key facts
- Who runs it
- Indapta Therapeutics, INC.
- Where
- Aurora, Kansas City, Orlando, St Louis, and Stanford, United StatesSee the 5 sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1
- People taking part
- 34 people, planned
- Started
- 30 Jun 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- IDP-023
- Ocrelizumab
- Interleukin-2
- Cyclophosphamide
- Fludarabine
- Mesna
- Record updated
- 30 April 2025
- Why it stopped
- Business Reasons
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Confirmed diagnosis of primary or non-active secondary progressive MS (SPMS) based on the 2017 revisions of the McDonald criteria
- Dosed with ocrelizumab within the prior 6 months
- Expanded Disability Status Scale (EDSS) at screening from 3.0 to 6.5 points
- Score of ≥2.0 on the Functional Systems (FS) scale for the pyramidal system that is due to lower extremity findings
- Disease duration from the onset of MS symptoms:; Less than 15 years in patients with an EDSS at screening >5.0; Less than 10 years in patients with an EDSS at screening ≤5.0
Who cannot take part
- Known presence of other neurological disorders, including but not limited to the following:; History or known presence of CNS or spinal cord tumor (e.g., meningioma, glioma); History or known presence of infectious causes of myelopathy (e.g., syphilis, Lyme disease, Human T-lymphotropic virus 1 [HTLV-1], herpes zoster myelopathy); History or known presence of systemic autoimmune disorders potentially causing progressive neurologic disease (e.g., lupus, antiphospholipid antibody syndrome, Sjögren's syndrome, Behçet's disease)
- Impaired cardiac function or history of clinical significant cardiac disease
- Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection
- Relapsing remitting MS at screening or active SPMS at screening
- Inability to complete an MRI
- Contraindication for gadolinium
Where in United States
- University of Colorado HospitalAurora, United States
- Kansas University Medical CenterKansas City, United States
- AdventHealth Orlando - Adventist Health System/Sunbelt, Inc.Orlando, United States
- Washington University in St. LouisSt Louis, United States
- Stanford UniversityStanford, United States
About the trial
What the trial wants to find out
This is an open label, Phase 1b, multiple ascending dose, and dose-expansion study of IDP-023 administered in combination with interleukin-2 (IL-2) and ocrelizumab to evaluate the safety, tolerability, and biologic activity on autoreactive immune cells in patients with refractory progressive multiple sclerosis.
The 2 groups in the trial
- Part 1 (dose escalation): IDP-023 in combination with IL-2 and ocrelizumabTreatment being tested
MS patients treated with multiple doses of IDP-023 in combination with IL-2 and ocrelizumab
Treatment: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna
- Part 2 (dose expansion): IDP-023 in combination with IL-2 and ocrelizumabTreatment being tested
MS patients treated with the recommended dose of IDP-023 in combination with IL-2 and ocrelizumab
Treatment: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1B Study of IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Refractory Primary and Secondary Progressive Multiple Sclerosis
- Record updated
- 30 April 2025